Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cost of Revenue (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Cost of Revenue data on record, last reported at $22.5 million in Q2 2025.

  • For Q2 2025, Cost of Revenue rose 8.96% year-over-year to $22.5 million; the TTM value through May 2025 reached $88.6 million, up 2.5%, while the annual FY2025 figure was $88.6 million, 2.5% up from the prior year.
  • Cost of Revenue reached $22.5 million in Q2 2025 per LFCR's latest filing, down from $25.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $31.2 million in Q3 2021 and bottomed at -$1.8 million in Q2 2022.
  • Average Cost of Revenue over 5 years is $20.1 million, with a median of $21.0 million recorded in 2024.
  • Peak YoY movement for Cost of Revenue: plummeted 106.09% in 2022, then surged 1365.13% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $11.0 million in 2021, then surged by 47.58% to $16.2 million in 2022, then rose by 24.77% to $20.2 million in 2023, then increased by 6.37% to $21.5 million in 2024, then increased by 4.57% to $22.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $22.5 million in Q2 2025, $25.3 million in Q1 2025, and $21.5 million in Q4 2024.